Cargando…
Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma
To identify prognostic factors in patients with grade 3 (high‐grade) endometrial endometrioid carcinoma, we evaluated the spectrum of genomic alterations and examined whether previously reported molecular subtypes of endometrial carcinoma were adapted to clinical outcome prediction. Seventy‐five Jap...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128156/ https://www.ncbi.nlm.nih.gov/pubmed/35278272 http://dx.doi.org/10.1111/cas.15328 |
_version_ | 1784712503122460672 |
---|---|
author | Kobayashi Kato, Mayumi Asami, Yuka Takayanagi, Daisuke Matsuda, Maiko Shimada, Yoko Hiranuma, Kengo Kuno, Ikumi Komatsu, Masaaki Hamamoto, Ryuji Matsumoto, Koji Ishikawa, Mitsuya Kohno, Takashi Kato, Tomoyasu Shiraishi, Kouya Yoshida, Hiroshi |
author_facet | Kobayashi Kato, Mayumi Asami, Yuka Takayanagi, Daisuke Matsuda, Maiko Shimada, Yoko Hiranuma, Kengo Kuno, Ikumi Komatsu, Masaaki Hamamoto, Ryuji Matsumoto, Koji Ishikawa, Mitsuya Kohno, Takashi Kato, Tomoyasu Shiraishi, Kouya Yoshida, Hiroshi |
author_sort | Kobayashi Kato, Mayumi |
collection | PubMed |
description | To identify prognostic factors in patients with grade 3 (high‐grade) endometrial endometrioid carcinoma, we evaluated the spectrum of genomic alterations and examined whether previously reported molecular subtypes of endometrial carcinoma were adapted to clinical outcome prediction. Seventy‐five Japanese patients with grade 3 endometrial endometrioid carcinoma, who underwent a potentially curative resection procedure between 1997 and 2018 at the National Cancer Center Hospital, were included. We classified the patients into four risk groups of the disease based on the Proactive Molecular Risk Classifier for Endometrial Cancer. Genomic alterations in PTEN, ARID1A, TP53, and PIK3CA were detected in more than 30% of the patients. Overall survival and recurrence‐free survival of patients with genomic alterations in CTNNB1 were poorer than those of patients with wild‐type CTNNB1 (p = 0.006 and p = 0.004, respectively). Compared with that of alterations prevalent in Caucasians, the frequency of genomic alterations in POLE and TP53 was higher in our study than in The Cancer Genome Atlas dataset (p = 0.01 and p = 0.01, respectively). The tendency for recurrence‐free survival in the POLE exonuclease domain mutation group was better than that in the TP53 mutation and mismatch repair‐deficient groups (p = 0.08 and p = 0.07, respectively), consistent with the Proactive Molecular Risk Classifier for Endometrial Cancer risk classifier definition. The CTNNB1 mutation is a potential novel biomarker for the prognosis of patients with grade 3 endometrial endometrioid carcinoma, and prognosis classification using Proactive Molecular Risk Classifier for Endometrial Cancer may help screen Japanese patients with the disease. |
format | Online Article Text |
id | pubmed-9128156 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91281562022-05-25 Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma Kobayashi Kato, Mayumi Asami, Yuka Takayanagi, Daisuke Matsuda, Maiko Shimada, Yoko Hiranuma, Kengo Kuno, Ikumi Komatsu, Masaaki Hamamoto, Ryuji Matsumoto, Koji Ishikawa, Mitsuya Kohno, Takashi Kato, Tomoyasu Shiraishi, Kouya Yoshida, Hiroshi Cancer Sci ORIGINAL ARTICLES To identify prognostic factors in patients with grade 3 (high‐grade) endometrial endometrioid carcinoma, we evaluated the spectrum of genomic alterations and examined whether previously reported molecular subtypes of endometrial carcinoma were adapted to clinical outcome prediction. Seventy‐five Japanese patients with grade 3 endometrial endometrioid carcinoma, who underwent a potentially curative resection procedure between 1997 and 2018 at the National Cancer Center Hospital, were included. We classified the patients into four risk groups of the disease based on the Proactive Molecular Risk Classifier for Endometrial Cancer. Genomic alterations in PTEN, ARID1A, TP53, and PIK3CA were detected in more than 30% of the patients. Overall survival and recurrence‐free survival of patients with genomic alterations in CTNNB1 were poorer than those of patients with wild‐type CTNNB1 (p = 0.006 and p = 0.004, respectively). Compared with that of alterations prevalent in Caucasians, the frequency of genomic alterations in POLE and TP53 was higher in our study than in The Cancer Genome Atlas dataset (p = 0.01 and p = 0.01, respectively). The tendency for recurrence‐free survival in the POLE exonuclease domain mutation group was better than that in the TP53 mutation and mismatch repair‐deficient groups (p = 0.08 and p = 0.07, respectively), consistent with the Proactive Molecular Risk Classifier for Endometrial Cancer risk classifier definition. The CTNNB1 mutation is a potential novel biomarker for the prognosis of patients with grade 3 endometrial endometrioid carcinoma, and prognosis classification using Proactive Molecular Risk Classifier for Endometrial Cancer may help screen Japanese patients with the disease. John Wiley and Sons Inc. 2022-03-24 2022-05 /pmc/articles/PMC9128156/ /pubmed/35278272 http://dx.doi.org/10.1111/cas.15328 Text en © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | ORIGINAL ARTICLES Kobayashi Kato, Mayumi Asami, Yuka Takayanagi, Daisuke Matsuda, Maiko Shimada, Yoko Hiranuma, Kengo Kuno, Ikumi Komatsu, Masaaki Hamamoto, Ryuji Matsumoto, Koji Ishikawa, Mitsuya Kohno, Takashi Kato, Tomoyasu Shiraishi, Kouya Yoshida, Hiroshi Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma |
title | Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma |
title_full | Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma |
title_fullStr | Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma |
title_full_unstemmed | Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma |
title_short | Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma |
title_sort | clinical impact of genetic alterations of ctnnb1 in patients with grade 3 endometrial endometrioid carcinoma |
topic | ORIGINAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128156/ https://www.ncbi.nlm.nih.gov/pubmed/35278272 http://dx.doi.org/10.1111/cas.15328 |
work_keys_str_mv | AT kobayashikatomayumi clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma AT asamiyuka clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma AT takayanagidaisuke clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma AT matsudamaiko clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma AT shimadayoko clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma AT hiranumakengo clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma AT kunoikumi clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma AT komatsumasaaki clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma AT hamamotoryuji clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma AT matsumotokoji clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma AT ishikawamitsuya clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma AT kohnotakashi clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma AT katotomoyasu clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma AT shiraishikouya clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma AT yoshidahiroshi clinicalimpactofgeneticalterationsofctnnb1inpatientswithgrade3endometrialendometrioidcarcinoma |